AstraZeneca PLC ADR falls Friday, underperforms market
The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
Could The Market Be Wrong About AstraZeneca PLC (LON:AZN) Given Its Attractive Financial Prospects?
AstraZeneca (LON:AZN) has had a rough month with its share price down 9.1%. But if you pay close attention, you ...
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...
BioWorld3d
Astrazeneca’s AZD-6234 prompts body weight loss due to reduced food intake
Amylin is a hormone co-secreted with insulin in the pancreas that has anorexigenic effects, since it promotes satiety and reduces food intake. Amylin analogs and dual agonists of the amylin and ...
Astra’s Blockbuster Drug Scores Major Win in Bladder Cancer
AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the ...
cnbctv185d
AstraZeneca’s blockbuster drug scores major win in bladder cancer
In patients with muscle-invasive bladder cancer, Imfinzi reduced the risk of disease recurring by 32% when given alongside ...
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the ...